The KDM5C Knockout NCI-H1975 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population in which the KDM5C gene has been disrupted in the NCI-H1975 human lung adenocarcinoma cell line. This loss-of-function model enables systematic investigation of KDM5C-dependent molecular mechanisms within an epithelial lung cancer background, providing a genetically defined system for functional genomics and epigenetic studies.
The NCI-H1975 parental cell line was originally established from a non-small cell lung adenocarcinoma of a non-smoking female patient. It is characterized by the presence of activating EGFR L858R and T790M mutations, which render the cells resistant to first-generation EGFR tyrosine kinase inhibitors. As an adherent epithelial cell line, NCI-H1975 is widely utilized as a model for tumorigenesis, metastatic dissemination, and the development of therapeutic resistance in lung adenocarcinoma.
KDM5C encodes a histone H3 lysine 4 (H3K4) demethylase that catalyzes the removal of tri-methyl groups (H3K4me3) from target gene promoters, thereby functioning as a transcriptional repressor. The activity of KDM5C is modulated by upstream regulators including E2F transcription factors, MYC, and TP53, and it operates within multiprotein complexes containing REST, SIN3A, HDAC1, HDAC2, and NCOR1 to orchestrate chromatin remodeling. Among its downstream transcriptional targets are the cell cycle inhibitors CDKN1A (p21) and CCND1 (cyclin D1), as well as neuronal differentiation genes. Through erasing H3K4me3 marks at these loci, KDM5C restricts their expression; its loss consequently derepresses these genes, promoting unchecked cell cycle progression and oncogenic transcription programs.
Given the established tumor-suppressive role of KDM5C via chromatin-mediated gene regulation, its disruption in NCI-H1975 cells creates a powerful tool to study the intersection of epigenetic dysregulation and lung adenocarcinoma aggressiveness. In a cellular context already driven by EGFR oncogenic signaling and TKI resistance, KDM5C knockout is predicted to exacerbate proliferative and survival phenotypes, offering a relevant model to dissect how histone methylation dynamics influence drug resistance and metastatic potential. This system aids in elucidating the contribution of KDM5C loss to the maintenance of malignant phenotypes in non-small cell lung cancer.
Typical experimental applications include chromatin immunoprecipitation combined with quantitative PCR (ChIP-qPCR) to map genome-wide H3K4me3 alterations, Western blotting and RT-qPCR to validate downstream target expression, and functional assays such as cell viability, colony formation, and migration assays to quantify phenotypic changes. The model is further amenable to in vivo xenograft studies to monitor tumor growth and drug sensitivity testing against EGFR inhibitors or epigenetic therapeutics. For additional product information or to discuss customized experimental strategies, please contact Ascent Research.
